Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [522]

Moles on the skin increase skin cancer risk

Dr Eugene Ong - University of Oxford, Oxford, UK

Moles on the skin increase skin cancer risk ( Dr Eugene Ong - University of Oxford, Oxford, UK )

One in ten UK doctors admit to using sunbeds

Dr Jingyuan Xu and Dr Kim Varma

One in ten UK doctors admit to using sunbeds ( Dr Jingyuan Xu and Dr Kim Varma )

ecancermedicalscience editor's choice for July and August 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for July and August 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Melanoma live: Making patient-focused therapy decisions

Prof Dirk Schadendorf; Dr Paul Nathan; Prof Georgina Long

Melanoma live: Making patient-focused therapy decisions ( Prof Dirk Schadendorf; Dr Paul Nathan; Prof Georgina Long )

Complexity of intra- and inter-pathway loops in colon cancer and melanoma:...

Prof René Bernards - Netherlands Cancer Institute, Amsterdam, The Netherlands

Complexity of intra- and inter-pathway loops in colon cancer and melanoma: Implications for targeted therapies ( Prof René Bernards - Netherlands Cancer Institute, Amsterdam, The Netherlands )

Combining immunological and targeted agents in melanoma

Dr Axel Hoos - GlaxoSmithKline, Collegeville, USA

Combining immunological and targeted agents in melanoma ( Dr Axel Hoos - GlaxoSmithKline, Collegeville, USA )

Advances in diagnostic devices in melanoma screening

Dr Alessandro Testori - European Institute of Oncology, Milan, Italy

Advances in diagnostic devices in melanoma screening ( Dr Alessandro Testori - European Institute of Oncology, Milan, Italy )

PD-1 targeting immunotherapy MK-3475 has high, long-lasting activity against...

Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, US

PD-1 targeting immunotherapy MK-3475 has high, long-lasting activity against metastatic melanoma ( Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, US )

Ipilimumab and nivolumab achieves long-term survival in advanced melanoma

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Ipilimumab and nivolumab achieves long-term survival in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III...

Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands

Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III melanoma ( Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands )

Comment: Adjuvant ipilimumab in high-risk melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Adjuvant ipilimumab in high-risk melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

More from ecancer